<DOC>
	<DOCNO>NCT03065764</DOCNO>
	<brief_summary>After screen phase 42 day , eligible subject undergo two whole body immuno-PET scan non-therapeutic tracer dose ( 2 mg ) 89Zr-pembrolizumab ; one one without precede `` cold '' therapeutic dose pembrolizumab . For first 3 patient , PET scan obtain 1 , 72 120 hour post tracer injection determine optimal scan time point perform biodistribution measurement dosimetry . All subsequent patient receive 1 PET scan post-injection ( i.e . two PET scan ) . The optimal time point expect day 5 post-injection . Pembrolizumab treatment continue every three week two year therapy administer , disease progression , unacceptable adverse event ( ) .</brief_summary>
	<brief_title>89Zr-labeled Pembrolizumab Patients With Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Have histologically cytologically confirm diagnosis stage IV , EGFR wt EML4/ALK fusion negative NCSLC receive least one line platinum base doublet chemotherapy disease progression RECIST 1.1 last systemic treatment . 2 . Be willing able provide write informed consent/assent trial . 3 . Be 18 year age , day signing inform consent . 4 . Have measurable disease base RECIST 1.1 . 5 . Must provide newly obtain tissue core excisional biopsy tumor lesion willing undergo second biopsy 89Zrpembrolizumab PET scan show heterogeneous uptake . 6 . Have performance status 02 ECOG Performance Scale . 7 . Demonstrate adequate organ function , screen lab perform within 10 day treatment initiation ( day 12 ) . 8 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 9 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 10 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 1 . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy dose high equivalent 10 mg prednisolone daily form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 4 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 5 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 6 . Has symptomatic central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects asymptomatic CNS metastasis allow enter study . Subjects previously treat brain metastasis may participate provide stable use steroid least 7 day prior trial treatment . 7 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . 8 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 9 . Has active infection require systemic therapy . 10 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 11 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 12 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 13 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . 14 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 15 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 16 . Has receive &gt; 30 Gy thoracic radiotherapy within 6 month start Pembrolizumab . 17 . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pembrolizumab</keyword>
	<keyword>89Zirconium</keyword>
</DOC>